Number of new cases globally per year

~78m

Gonorrhoea has been identified as one of three urgent threats by the US Centers for Disease Control and Prevention (‘CDC’) and a high priority pathogen by the World Health Organisation.

Our research programme is developing new mechanism antibiotics to treat all gonorrhoea.

ABOUT GONORRHOEA

Gonorrhoea has been identified as one of three urgent threats by the US Centers for Disease Control and Prevention (‘CDC’) and . It is estimated by the World Health Organization (‘WHO’) that there are approximately 78 million new cases of gonorrhoea globally per year. The US CDC reported in 2013 that 30% of new cases are resistant to at least one of the antibiotics currently used to treat gonorrhoea. Further the organism responsible for this infectious disease, Neisseria gonorrhoea, has consistently developed resistance to each class of antibiotics recommended for treatment and there is now only one treatment recommended by the CDC, a combination of two antibiotics which is approaching the point at which its use should be stopped. There are currently no other antibiotics that can be effectively deployed to target the disease. The WHO ranks as “High” the priority of R&D investment into the search for antibiotics which are effective against N. gonorrhoeae.

 

NOVEL MECHANISM ANTIBIOTICS FOR GONORRHOEA

Using our proprietary Discuva Platform, we have identified two novel targets that can kill the bacteria Niesseria gonorrhoeae. We have also discovered two distinct series of antibiotic compounds against these targets. In early-testing, these series of antibiotics has been shown to have  high potency against gonorrhoea bacteria with no development of resistance to date.

Summit has presented data on its gonorrhoea programme at major international conferences including ASM Microbe 2018. All presentations can be found in the publications section.

We believe the two series of antibiotic compounds in development have the potential to produce a new front-line therapy for gonorrhoea. Our aim is to select a candidate from the the lead series of compounds for progression into IND enabling studies in the second half of 2018.